EP Patent

EP3765488A1 — Process for the manufacture of pthrp analogue

Assigned to Fresenius Kabi Ipsum SRL · Expires 2021-01-20 · 5y expired

What this patent protects

The present invention relates to a fragment based manufacturing process for abaloparatide, which is an analogue of parathyroid hormone related peptide (PTHrP), and its related intermediates resulting in a product with high yield and high purity.

USPTO Abstract

The present invention relates to a fragment based manufacturing process for abaloparatide, which is an analogue of parathyroid hormone related peptide (PTHrP), and its related intermediates resulting in a product with high yield and high purity.

Drugs covered by this patent

Patent Metadata

Patent number
EP3765488A1
Jurisdiction
EP
Classification
—
Expires
2021-01-20
Drug substance claim
No
Drug product claim
No
Assignee
Fresenius Kabi Ipsum SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.